Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors.
about
Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cellsRole of multifaceted regulators in cancer glucose metabolism and their clinical significanceProgress toward overcoming hypoxia-induced resistance to solid tumor therapyRole of hypoxia-inducible factors in breast cancer metastasisCancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasisNewly discovered angiogenesis inhibitors and their mechanisms of actionHypoxia-inducible aryl hydrocarbon receptor nuclear translocator (ARNT) (HIF-1β): is it a rare exception?Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.Candidate biomarkers for cervical cancer treatment: Potential for clinical practice (Review).Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targetsFirst-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignanciesEffects of hypoxia on human cancer cell line chemosensitivity.The antioxidant N-acetylcysteine prevents HIF-1 stabilization under hypoxia in vitro but does not affect tumorigenesis in multiple breast cancer models in vivo.Hypoxia and the extracellular matrix: drivers of tumour metastasisEvaluation of anti-HIF and anti-angiogenic properties of honokiol for the treatment of ocular neovascular diseases.Intravitreal Topotecan Inhibits Laser-induced Choroidal Neovascularization in a Rat Model.An in vitro assessment of liposomal topotecan simulating metronomic chemotherapy in combination with radiation in tumor-endothelial spheroids.Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis.Molecular mechanisms mediating metastasis of hypoxic breast cancer cells.Recent Advances in Targeting Tumor Energy Metabolism with Tumor Acidosis as a Biomarker of Drug Efficacy.Validation of a hypoxia-inducible factor-1 alpha specimen collection procedure and quantitative enzyme-linked immunosorbent assay in solid tumor tissues.Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes.Cisplatin treatment increases stemness through upregulation of hypoxia-inducible factors by interleukin-6 in non-small cell lung cancer.Perspective: Opportunities in recalcitrant, rare and neglected tumors.Targeting the metabolic microenvironment of tumors.Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis.The potential role of HIF on tumour progression and dissemination.Metronomics: towards personalized chemotherapy?A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials.Clinical overview of metronomic chemotherapy in breast cancer.Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling.Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathwaysThe chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells.The role of metabolic reprogramming in γ-herpesvirus-associated oncogenesis.Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trialInhibition of hypoxia inducible factors combined with all-trans retinoic acid treatment enhances glial transdifferentiation of neuroblastoma cells.Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development.Hypoxia and Inflammation in Cancer, Focus on HIF and NF-κB.Epstein–Barr Virus-Induced Metabolic Rearrangements in Human B-Cell Lymphomas.
P2860
Q24613508-92C056C6-211A-4D2D-83F1-0971B7E51923Q26765039-932D70DA-35A3-4132-85B3-2927F1D876C0Q26796405-BA31CCE6-7C0D-46EF-92CA-4CCC468D6449Q26860122-C30B6A65-24C9-4878-9AB3-6B93F472A3C0Q26866144-D5B15979-E888-412F-ACD5-C89C358A4BBCQ26998498-73EBC639-4175-4F5A-BE96-C643CB8BB346Q27027475-42D25B22-D5FE-4015-B17A-9CE3AB83F7ABQ33439523-0D949845-95B6-4C95-ABF5-17BF9D1A0876Q33933054-E67FBF4C-75D7-447F-A0F3-0F3EC1829191Q34023663-48BDCFF8-D6A2-46B4-9112-90BC10C3C82EQ34327123-E29D88D5-D907-4790-929A-5143E7AEA7D9Q34799788-7FB13F1D-33F8-4862-A327-2C305888AFF9Q34805346-B4E8BF7E-F7CD-4CC4-B846-DE7442536E53Q34820282-3A0B82C2-0C83-4C71-97DC-6A73BBB4836BQ35448249-1FF56061-8EEE-4BB2-ABED-153A44EE3BA2Q35884935-C0E1C9CD-9133-46DE-93E2-677523E1242BQ36163874-61D05CAC-15FE-409A-957F-941913847C39Q36220497-7594C994-47E2-4090-AC76-A9FE0DD59A7EQ36220525-314B5B16-93F0-421A-BE3B-DFCC2423827BQ36254122-E65F3D40-AF5D-4085-BC09-DB6EF86BE2E0Q36658324-A4F7B33C-A7FC-46BB-8E8A-EEE0B8AD9576Q36737058-799732DE-8D48-411A-BC0E-E926CD4F9A0AQ36926098-BBA7199D-CB6D-4FB8-A838-BC9F07BBDAB6Q37142438-FC4A078D-1B23-41D6-8C7D-94C4557D75E0Q37197528-91A7752F-FDF6-402B-B04B-2F74790A17CAQ37229190-EDB3D478-F3E7-46DF-9A40-D426CAA535D1Q37520563-5F55A44C-8759-404D-A8BF-4B054563FFCFQ38204343-17E9B00C-8891-488F-82B4-1CD2CEC35288Q38218923-257211A4-70B8-4A29-88BE-F69D15C166AEQ38249998-EEFAB8E1-103B-4CD9-BB97-0C14B47E2457Q38560651-BF84DC68-ECB8-4682-B5AC-76524AF56F0DQ38777221-7C3CAA67-054B-4491-994D-CABFB534B116Q39077231-9AB3B940-ECE7-43E5-BAB6-D7AB3F0F8EBFQ39153126-90433B06-3F8F-4CE6-BDD3-372DDAF66969Q39329214-830C1B85-A64E-4883-924C-1C70762C7074Q40600188-8264A0AF-2E6A-4153-A48D-EAA713580D4DQ40854486-642EC414-1D2E-4849-9018-C549FA1624A4Q52726721-7D9216C0-F36A-490F-9402-6753C6219752Q54858561-A449FACD-BA7C-415A-A02D-9A92C0B0A5ADQ55272984-E9233795-E853-4B82-9DF5-8BE47568E976
P2860
Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Multihistology, target-driven ...... r-1α in advanced solid tumors.
@ast
Multihistology, target-driven ...... r-1α in advanced solid tumors.
@en
type
label
Multihistology, target-driven ...... r-1α in advanced solid tumors.
@ast
Multihistology, target-driven ...... r-1α in advanced solid tumors.
@en
prefLabel
Multihistology, target-driven ...... r-1α in advanced solid tumors.
@ast
Multihistology, target-driven ...... r-1α in advanced solid tumors.
@en
P2093
P2860
P1476
Multihistology, target-driven ...... r-1α in advanced solid tumors.
@en
P2093
Agnes Strassberger
Annamaria Rapisarda
Anthony J Murgo
Deborah Allen
Giovanni Melillo
Ismail Baris Turkbey
James H Doroshow
Lamin Juwara
Mark Raffeld
Peter Choyke
P2860
P304
P356
10.1158/1078-0432.CCR-11-0682
P407
P577
2011-06-14T00:00:00Z